Abstracts Archive - Page 576 of 2607 - ACR Meeting Abstracts

Abstract Number: 1385 • ACR Convergence 2022
Clinical and Serologic Characterization of Juvenile Systemic Sclerosis Overlap Disease
Amanda Robinson and Kathryn Torok, Pediatric Rheumatology, Children's Hospital of UPMC, Pittsburgh, PA
Background/Purpose: Juvenile systemic sclerosis (jSSc) is a systemic fibroinflammatory autoimmune disease characterized by skin fibrosis and multiple extracutaneous manifestations. A proportion of children with jSSc…
Abstract Number: 1397 • ACR Convergence 2022
The Impact of Disease Activity on Patient-Reported Cognitive Dysfunction in Rheumatoid Arthritis
Ozlem Pala¹, Dimitrios Pappas², George Reed³ and Joel Kremer⁴, ¹University of Miami, Fort Lauderdale, FL, ²Corrona Research Foundation; CorEvitas, LLC, Albany, NY, ³University of Massachusetts Medical School, Worcester, MA, ⁴The Corrona Research Foundation, Delray Beach, FL
Background/Purpose: Rheumatoid Arthritis (RA) is a systemic, inflammatory disease, and its burden extends beyond joint disease. RA is not commonly associated with central nervous system…
Abstract Number: 1398 • ACR Convergence 2022
Myokine Myostatin Is a Novel Predictor of One-year Radiographic Progression in Patients with Rheumatoid Arthritis
Jian-Zi Lin, Li-Juan Yang, Hong-Gui Li, Ai-Qi Zeng, Kui-Min Yang and Lie Dai, Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China
Background/Purpose: Associations between rheumatoid arthritis (RA) and reduced skeletal muscle have been studied, and we firstly reported myopenia independently predict one-year radiographic progression in RA.…
Abstract Number: 1388 • ACR Convergence 2022
Updating and Validating the Rheumatic Disease Comorbidity Index to Incorporate ICD-10 Diagnostic Codes
Anthony Dolomisiewicz¹, Hanifah Ali², Punyasha Roul³, Yangyuna Yang¹, Grant Cannon⁴, Joshua Baker⁵, Ted Mikuls⁶, Kaleb Michaud¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC, Omaha, ³UNMC, Omaha, NE, ⁴Salt Lake City VA, Salt Lake city, ⁵University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ⁶Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The Rheumatic Disease Comorbidity Index (RDCI) was designed to quantify comorbidity burden for risk stratification of health outcomes in patients with rheumatic disease. Developed…
Abstract Number: 1396 • ACR Convergence 2022
Risk of Hospitalized Infections in Older Elderly Rheumatoid Arthritis Patients Treated with Biological/Targeted Synthetic DMARDs: Evaluation Using Data from a Japanese Claims Database
Masayoshi Harigai¹, Takao Fujii², Ryoko Sakai³, Ataru Igarashi⁴, Ayako Shoji⁵, Hiroko Yamaguchi⁶, Katsuhiko Iwasaki⁶, Misako Makishima⁷, Amika Yoshida⁷, Norihiro Okada⁷, Katsuhisa Yamashita⁷ and Yutaka Kawahito⁸, ¹Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ²Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan, ³Department of Public Health and Epidemiology, Meiji Pharmaceutical University, Tokyo, Japan, ⁴Department of Health Economics & Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan; Unit of Public Health and Preventive Medicine, Yokohama City University of Medicine, Kanagawa, Japan, ⁵Medilead Inc., Tokyo, Japan; Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan; Healthcare Consulting Inc., Tokyo, Japan, Shinjuku-ku, Japan, ⁶Medilead Inc., Tokyo, Japan, Shinjuku-ku, Japan, ⁷Chugai Pharmaceutical Co., Ltd., Chuo-ku, Tokyo, Japan, ⁸Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, Kyoto, Kyoto, Japan
Background/Purpose: Safety evidence of biological or targeted synthetic DMARDs (b/tsDMARDs) is still insufficient in older elderly ( >=75 years old (y/o)) patients with rheumatoid arthritis…
Abstract Number: 1409 • ACR Convergence 2022
Impact of a Hybrid Medical Care Model in the Rheumatoid Arthritis Patient-Reported Outcomes: A Non-inferiority Crossover Randomized Study
Guillermo Guaracha Basañez¹, Irazu Contreras-Yáñez², Vivian Estrada-González², Lexli Pacheco-Santiago², Salvador Valverde-Hernández² and Virginia Pascual Ramos³, ¹Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirn", Ciudad de México, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ³Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Mexico
Background/Purpose: Patients and physicians can naturally adopt hybrid healthcare models (HC), that combine face-to-face consultations (FFC) with telemedicine. The study's objective was to compare the…
Abstract Number: 1403 • ACR Convergence 2022
Herpes Zoster in Rheumatoid Arthritis: Prospective Single University Center Study
Lucia Cristina Dominguez Casas¹, Mª Paz Rodriguez Cundin², Trinidad Dierssen Sotos³, Nuria Vegas Revenga⁴, Alfonso Corrales⁵, Miguel Ángel González-Gay⁶ and Ricardo Blanco⁷, ¹Hospital Universtario San Agustin, Oviedo, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Universidad de Cantabria, Santander, Spain, ⁴Hospital Galdakao- Usansolo, Galdakao, Spain, ⁵Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁷Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Patients with Rheumatoid arthritis (RA) have an increased risk of infections due to the disease itself, and/or immunosuppressive therapy. The risk of herpes zoster…
Abstract Number: 1405 • ACR Convergence 2022
In Contrast to Anti-CCP, Then MMP Degraded and Citrullinated Vimentin (VICM) Is Both a Diagnostic and Treatment Response Biomarker
Patryk Drobinski¹, Neel I. Nissen¹, morten A. Karsdal², Nicholas Willumsen² and Anne-Christine Bay-Jensen², ¹University of Copenhagen, Copenhagen, Denmark, ²Nordic Bioscience, Herlev, Denmark
Background/Purpose: The degree of protein citrullination and degradation by matrix metalloproteinases (MMP) play a central role in the pathology of rheumatoid arthritis (RA). Autoantibodies are…
Abstract Number: 1401 • ACR Convergence 2022
Relationship Between Disease Activity and Adverse Events of Interest in Patients with RA on Tofacitinib or TNF Inhibitors: Post Hoc Analysis of a Phase 3b/4 Randomized Safety Study
George A Karpouzas¹, Zoltan Szekanecz², Eva Baecklund³, Ted Mikuls⁴, Deepak L Bhatt⁵, Harry Shi⁶, Cunshan Wang⁷, Gosford A Sawyerr⁸, Yan Chen⁶, Sujatha Menon⁷, Carol A Connell⁷, Steven R Ytterberg⁹ and Mahta Mortezavi⁸, ¹Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²Division of Rheumatology, Faculty of Medicine, Debrecen, Hungary, ³Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ⁴Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁵Department of Cardiovascular Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁶Pfizer, Inc, Collegeville, PA, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, New York, NY, ⁹Division of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Uncontrolled RA activity and acute disease flares are associated with higher risk of adverse outcomes, such as cardiovascular (CV) disease, venous thromboembolism (VTE), malignancy,…
Abstract Number: 1412 • ACR Convergence 2022
Coronary Microvascular Dysfunction in Patients with Rheumatoid Arthritis and Diabetes Mellitus: A Cross-sectional Study with 13NH3 Myocardial PET/CT
Bas Dijkshoorn¹, Remco Knol², Friso Van Der Zant², Michael Nurmohamed³ and Suat Simsek², ¹Reade Rheumatology Center, Amsterdam, Netherlands, ²Noord-west Ziekenhuis groep, Alkmaar, Netherlands, ³Amsterdam University Medical Center, Kortenhoef, Netherlands
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular disease. This risk is similar to that of diabetes mellitus (DM). There have…
Abstract Number: 1411 • ACR Convergence 2022
Predictors of Achieving Clinical Remission in ACPA-positive RA-patients Treated with Abatacept and Methotrexate or Methotrexate Monotherapy
Marloes Verstappen¹, Ellis Niemantsverdriet², Tom Huizinga¹, Annette van der Helm-van Mil³ and Sytske Anne Bergstra², ¹Leiden University Medical Center, Leiden, Netherlands, ²LUMC, Leiden, Netherlands, ³Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: With a wide range of disease modifying treatment available, clinical remission is frequently achieved in rheumatoid arthritis (RA). Although a proportion of RA-patients achieves…
Abstract Number: 1413 • ACR Convergence 2022
Early Muscle Involvement in Patients with Rheumatoid Arthritis: A Large-Scale Cross-Sectional Study
Jie Pan¹, Yao-Wei Zou¹, Ying-Ying Zhu², Jian-da Ma³, Jian-Zi Lin³, Tao Wu¹, Ze-Hong Yang², Xue-Pei Zhang¹, Qian Zhang¹, Hu-Wei Zheng¹, Xiao-Ling He⁴, Wan-Mei Cheng⁴ and Lie Dai³, ¹Sun Yat-Sen University, Guangzhou, China, ²Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, ³Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China, ⁴Shanghai Healthare Co. Ltd, Shang hai, China
Background/Purpose: Muscle loss is common in long-standing rheumatoid arthritis (RA) patients. However, less is known about this unfavorable alteration of body composition (BC) and its…
Abstract Number: 1355 • ACR Convergence 2022
Relationships Between Work Productivity, Activity Impairment, and Select Patient-Reported Outcomes in Patients with Ankylosing Spondylitis: A Post Hoc Analysis of Two Placebo-Controlled Trials
Marina Magrey¹, James Cheng-Chung WEI², Arne Yndestad³, Andrew Bushmakin⁴, Joseph Cappelleri⁴, Oluwaseyi Dina⁵ and Atul Deodhar⁶, ¹Case Western Reserve University, University Hospitals, Richfield, OH, ²Chung Shan Medical University Hospital, Taichung, Taiwan, ³Pfizer Inc, Oslo, Norway, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶Oregon Health & Science University, Portland, OR, USA, Portland, OR
Background/Purpose: Patients (pts) with AS often experience impaired work productivity.1 In pts with AS receiving tofacitinib (oral Janus kinase inhibitor), improvements were observed in work…
Abstract Number: 1304 • ACR Convergence 2022
Glucocorticoids Affect Bone Mass and Strength by Inhibiting Osteoprogenitor Cell Maturation
Thomas Ambrosi¹, Mathew Murphy¹, Charles KF Chan¹ and Nancy Lane², ¹Stanford University, Stanford, CA, ²University of California Davis, Hillsborough, CA
Background/Purpose: Glucocorticoid (GC) induced osteoporosis remains a significant health issue. While GCs are known to reduce bone formation and bone mass, patients treated with GCs…
Abstract Number: 1160 • ACR Convergence 2022
Mapping Spondyloarthritis Susceptibility Loci in B10.RIII Mice
Jyotsna Soundararajan¹, Anu Shivalikanjli², Thomas Keane² and Joerg Ermann³, ¹Brigham and Women's Hospital, Boston, MA, ²European Molecular Biology Laboratory, European Bioinformatics Institute, Cambridge, United Kingdom, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Overexpression of IL-23 using IL-23 minicircle DNA in B10.RIII mice results in the development of a spondyloarthritis-like disease. B10.RIII (B10.RIII-H2r H2-T18b/(71NS)SnJ) is a major…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].